podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 15/22 Podcast
  4. Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
Background: Due to increasing drug resistance, artemisinin-based
combination chemotherapy (ACT) has become the first-line treatment
of falciparum malaria in many endemic countries. However,
irreversible ototoxicity associated with artemether/lumefantrine
(AL) has been reported recently and suggested to be a serious
limitation in the use of ACT. The aim of the study was to compare
ototoxicity, tolerability, and efficacy of ACT with that of quinine
and atovaquone/proguanil in the treatment of uncomplicated
falciparum malaria. Methods: Ninety-seven patients in south-west
Ethiopia with slide-confirmed malaria were randomly assigned to
receive either artemether/lumefantrine or quinine or
atovaquone/proguanil and followed-up for 90 days. Comprehensive
audiovestibular testing by pure tone audiometry (PTA), transitory
evoked (TE) and distortion product (DP) otoacoustic emissions (OAE)
and brain stem evoked response audiometry (BERA) was done before
enrolment and after seven, 28 and 90 days. Results: PTA and DP-OAE
levels revealed transient significant cochlear hearing loss in
patients treated with quinine but not in those treated with
artemether/lumefantrine or atovaquone/proguanil. TE-OAE could be
elicited in all examinations, except for three patients in the Q
group on day 7, who suffered a transient hearing loss greater than
30 dB. There was no evidence of drug-induced brain stem lesions by
BERA measurements. Conclusion: There was no detrimental effect of a
standard oral regimen of artemether/lumefantrine on peripheral
hearing or brainstem auditory pathways in patients with
uncomplicated falciparum malaria. In contrast, transient hearing
loss is common after quinine therapy and due to temporary outer
hair cell dysfunction.

Weitere Episoden

Report of the Working Group `Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)'

Report of the Working Group `Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)'

vor 17 Jahren
Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial

Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial

vor 17 Jahren
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

vor 17 Jahren
JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.

JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.

vor 17 Jahren
Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.

Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.

vor 17 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz